Able Laboratories of Cranbury, New Jersey, received a list of "inspectional observations" from the FDA in connection to its product recall announcement and suspension of manufacturing operations. The tersely written inspection notice was announced on Friday, the same day that Able's interim CEO -- Robert G. Mauro -- resigned from his post. The generic drug maker says that it cannot be certain when or if operations will resume.
- read this press release for more